NeuTecPharma.com

NeuTec Pharma Ltd. was a Pharmaceuticals company located in Lloyd St N, Manchester, United Kingdom. This site was developed by Pharma around 2003 to promote their company and NeuTec's two leading products Mycograb® and Aurograb®. In July 2006 the company was acquired by Novartis Pharma AG. The site's domain eventually expired and the information regarding NeuTecPharma Ltd disappeared from the WWW.

In 2009 I was working for a small progressive software company. I do a lot of custom software development for the company's clients as an experienced Salesforce consultant. One of the most exciting areas is happening in healthcare analytics. As far as I am concerned the use of healthcare big data to improve patient care and healthcare deliverables is still in its inception. Companies in the health field marketplace are clamoring for custom software.However, Salesforce recognized the need and is setting a new standard for patient management software that goes beyond electronic medical records alone. Most of us developers as well as health care companies' IT folks feel that we have only scratched the surface of what the clinical data can be used for and how health care analytics can change the face of healthcare as we now know it. It just happened to turn out that my company did some pro bono work for a community that was a recipient of some of an SIF grant. I was in London, UK attending a 2006 conference about the use of healthcare data analytics with the Salesforce Health Cloud platform and how it can revolutionize the entire healthcare industry. The conference was a means for my company to network, perhaps find new clients, as well as contribute to the ongoing discussions regarding health care analytics etc. The conference was informative. I took a side trip to see a potential client in Manchester where NeuTec Pharma Ltd. was located. It seemed that everyone I met was talking about Novartis Pharma AG acquiring NeuTec Pharma Ltd and what it might mean for the pharma industry. in all it was a successful trip with my aquiring a number of good leads. I continued to follow the two drugs, Mycograb® and Aurograb®. In 2008 Novartis decided to pull the plug on Aurograb. Pundits said that Novartis' high-premium $569m takeover of NeuTec Pharma in 2006 was perhaps now looking like an increasingly expensive mistake. Then in 2010 Novartis abandoned their continuing development of anti-fungal agent Mycograb, highlighting the high cost of R&D failure in the pharma industry.

Nevertheless when I recently discovered that the domain was available, I bought it with the intent of restoring some of its original content found in its archived pages. ​I believe that the information on neutecpharma.com's archived pages is still important and should be available for online​ viewing if for no other reason than for historical purposes​.

PLEASE NOTE THAT THIS PAGE CONTAINS SELECTED ARCHIVED CONTENT FROM THE ORIGINAL SITE.

Mycograb®

Mycograb®, is a “grab” targeting the immunodominant antigen heat shock protein 90 (“hsp90”) for the treatment of systemic candidiasis. This is a life-threatening fungal infection most commonly due to the yeast species Candida albicans and, less commonly, Candida krusei, Candida parapsilosis or Candida tropicalis.

Systemic fungal infections are estimated at 320,000 incidences per year worldwide. Most common is systemic candidiasis, representing approximately 70 per cent of all such infections with a mortality rate of up to 40 per cent. Mycograb® has completed a confirmatory study in the treatment of systemic candidiasis and has applied to the EMEA for market approval in Europe.  The drug may also be active against other fungal infections and breast cancer.

At particular risk are low birth-weight babies, post surgical patients, patients whose immune systems have been compromised, such as by therapies for cancer, bone marrow transplant recipients and patients on peritoneal dialysis. For example, in a German study, over 12 per cent of patients receiving bone marrow transplants developed systemic candidiasis. Indeed general medical advances in these areas over recent decades have almost certainly contributed to an increase in the number of patients at risk.

The standard therapy for the treatment of systemic candidiasis is amphotericin B which is available off- licence. Whilst it is inexpensive and widely prescribed, its use is limited by toxicity and lack of efficacy. Severe reactions, especially kidney and liver toxicity, are common and so, to reduce the incidence of such side-effects, more expensive lipid-based formulations are widely used. These are less toxic but have not been associated with improved efficacy. Alternatively, drugs such as fluconazole can be given although certain species of Candida, such as Candida krusei, are intrinsically resistant and indeed fluconazole resistance has now emerged in Candida albicans itself. Accordingly, there is a need for a more effective and safe form of treatment for Candida with a broad spectrum of activity.

Since 1998, Mycograb® has developed from a crude preparation produced in two litre batches in the laboratory into a well defined product manufactured to GMP standards in a large scale fermenter. Over this period the company has itself built up substantial technical knowledge regarding the processes required to achieve successful large scale production and GMP compliance including the fermentation, downstream processing and freeze drying of the final purified product.

The final formulation and convenient method of storage, as a stable freeze dried powder in glass vials, was developed in-house and then optimised using the large scale facilities of a third party manufacturer.

Mycograb® has the following properties as an antifungal agent:

• intrinsic antifungal activity;
• synergistic activity with amphotericin B: the combined use of the two agents together giving greater activity than either agent alone; and
• a broad spectrum of activity against all Candida species examined including fluconazole-resistant Candida albicans and Candida krusei.

This activity has been demonstrated using laboratory assays analogous to those used to test traditional antifungal agents including minimum inhibitory levels and models of the infection. Given its synergy with amphotericin B, Mycograb® was evaluated in a confirmatory clinical trial in combination with liposomal preparations of amphotericin B (Abelcet and AmBisome) to determine whether this combination therapy is more effective than amphotericin B alone.

The hsp90 antigen targeted by Mycograb® is also present in the fungus Aspergillus which is the cause of invasive aspergillosis, a less common but even more lethal systemic fungal infection. Preliminary laboratory data suggests Mycograb® may also have activity against this fungus and future clinical trials may investigate the efficacy of Mycograb® against invasive aspergillosis.

Additionally, a successful application to the FDA for an Investigational New Drug (“IND”) has been achieved for a phase III study to assess the efficacy and safety of Mycograb® as adjunctive therapy for cryptococcal meningitis in patients with AIDS. The trial will take place in centres in the USA, South America and South Africa.

Orphan Drug Status has been granted in Europe by the EMEA and in the USA by the FDA for the use of Mycograb® against invasive fungal infections including systemic candidiasis and invasive aspergillosis.

Mycograb® positive clinical results:

In July 2004 the company announced the successful achievement of clinical end points from a multinational, double-blind, placebo-controlled trial involving 10 European countries and the USA. The trial was conducted in 139 patients with invasive candidiasis who received conventional treatment with lipid-based formulation of amphotericin B combined with a five day course of either Mycograb® or placebo.

• Primary end point - 84% overall response rate vs 48% in placebo control group: To be regarded as a success, patients had to show both a complete clinical response ("cure") and a mycological response (culture-confirmed clearance of the infection in the laboratory) at Day 10. The trial showed a highly statistically significant difference (P value < 0.001) in the overall response rates (clinical and mycological response) between the placebo control group and those receiving Mycograb®. The positive response rate of the group receiving mono-therapy was 48% compared to 84% in the group recieving Mycograb® with amphotericin B.
• Secondary end point - In addition, separate analysis of each of the two components (clinical response and mycological response) showed a highly statistically significant difference between the two groups (P value < 0.001).
• Secondary end point - less deaths due to candidal infection: In the group receiving mono-therapy, candida-attributable mortality was 18%, whereas in the group receiving additional therapy with Mycograb® this fell to 4%, a statistically signifiant difference (P value < 0.025).
• Secondary end point - faster eradication of fungus: A highly statistically significant difference between the two groups (P value <0.001) occurred in the rate of culture-confirmed clearance of the infection (Mycograb® 3 days, mono-therapy 23 days).
• In March 2005 a validated application was made to the EMEA for market authorisation in the treatment of invasive candidiasis.

Breast Cancer

In September 2005 the company commenced a clinical study in breast cancer patients. The phase Ib, pharmacokinetic, multi-centre, open label study evaluated the safety and efficacy of Mycograb® administered in combination with Docetaxel in metastatic or recurrent breast cancer patients.

According to the American Cancer Society, breast cancer is the most common cancer among women, except for non-melanoma skin cancers and it is estimated that in 2005 about 211,240 new cases of invasive breast cancer will be diagnosed among women in the United States. Breast cancer is the second leading cause of cancer death in women, exceeded only by lung cancer. The chance that breast cancer will be responsible for a women’s death is about 1 in 33 (3%). In 2005, about 40,110 women and 470 men will die from breast cancer in the United States. Currently there is no curative therapy for metastatic breast cancer despite early diagnosis, and the five year survival rate for advanced cancers is only 18%.

Mycograb® is a human genetically recombinant antibody (‘grab’) that binds to heat shock protein 90 (‘hsp90’) which has been identified as a tumour marker which appears on the outside of certain cancer cells (as with fungi) and is needed for cancer cell survival. The growth of cancer cells is particularly sensitive to the effects of hsp90’s inhibition and this anti-cancer activity has been seen in a series of vitro studies looking at the killing of human cancer cell lines.

There have been over 460 papers describing the involvement of hsp90 in the development of cancer. Consequently, hsp90 proteins are widely being evaluated as targets for cancer chemotherapy in combination with other drugs and as stand alone therapy. There are 21 on-going trials, involving a variety of cancers, using agents based on variants of the chemical hsp90 inhibitor geldanamycin. Dose-limiting toxicity, however, is a major hurdle in the development of chemical hsp90 inhibitors. Mycograb® differs from all other hsp90 inhibitors in having been originally developed for the treatment of fungal infections.

Aurograb®

Aurograb® is a "grab" targeting Staphylococcus aureus including MRSA and the recently emerged VISA. Staphylococcus aureus is the bacterium responsible for the largest proportion of hospital-acquired bacterial infections. MRSA is now endemic in hospitals around the world with an estimated 1.5 million cases per year worldwide. MRSA causes significant morbidity with mortality from MRSA bloodstream infections of up to 50 per cent.

Vancomycin is an antibiotic of last resort being a cause of nephrotoxicity, ototoxicity and bone marrow toxicity. Moreover, intermediate sensitivity to vancomycin has recently surfaced among MRSA strains in Japan, the USA and Europe. The emergence of VISA has been described by The Lancet as an “apocalypse now” scenario and highlights the need for new and more effective therapies.

cGMP manufacture of Aurograb® was completed in June 2001 involving fermentation, downstream processing and freeze drying batches of the final purified product. Pre-clinical studies were successfully completed in November 2001 and a CTX was successfully applied for from the MCA in January 2002. Clinical trials commenced in mid 2002.

Aurograb® has the following properties as an antistaphylococcal agent:

1. intrinsic activity against staphylococci;
2. synergistic activity with vancomycin: the combined use of the two agents together giving greater activity than either agent alone; and
3. a broad spectrum of activity against different strains of Staphylococcus aureus including the currently circulating epidemic strains of MRSA and VISA.

This activity has been demonstrated using laboratory assays analogous to those used to test antistaphylococcal antibiotics, including minimum inhibitory levels and models of the infection. Given its synergy with vancomycin, the company anticipates that Aurograb® will be of particular benefit when prescribed in combination with vancomycin in the treatment of MRSA infections, both increasing efficacy and inhibiting the emergence of VISA.

In June 2006 the company completed a double-blind placebo-controlled phase III clinical trial. The study carried out in a total of 35 centres in 6 European countries and involved the recruitment of 161 adult hospitalized patients with deep-seated staphylococcal infections. The trial compared the effects of Aurograb® in combination with vancomycin versus vancomycin alone in the treatment of MRSA infections.

This trial follows the earlier phase IIb study which was completed in June 2003 and found the drug to be well tolerated and demonstrated a profile that supports likely activity against MRSA in man. Aurograb® has activity on its own against strains of MRSA, but when combined with vancomycin, the current “gold standard” treatment, is more effective than either drug used on its own. The activity is also evident in strains with partial resistance to vancomycin or linezolid. Fully resistant strains to vancomycin have also been reported.

More Background On NeuTecPharma.com

NeuTecPharma.com represents the digital legacy of a once-promising British biotechnology company that attracted significant attention in the early 2000s for its innovative work in recombinant antibody therapies targeting life-threatening infections. The company behind the site, NeuTec Pharma Ltd, emerged during an era when pharmaceutical and biotechnology firms were aggressively searching for alternatives to traditional antibiotics amid growing fears over antimicrobial resistance, hospital-acquired infections, and invasive fungal diseases.

The original NeuTecPharma.com website functioned as the company’s primary corporate and scientific communications platform. It detailed NeuTec’s antibody-based therapeutic technology, highlighted clinical trial milestones, and promoted the company’s flagship investigational products: Mycograb® and Aurograb®. Years after the company disappeared following its acquisition by Novartis, the domain resurfaced as a historical preservation project intended to restore and archive portions of the original website for educational and historical purposes.

Today, NeuTecPharma.com serves as both a memorial to a biotech company that once generated major excitement within pharmaceutical circles and a snapshot of a transformative period in biotechnology when recombinant antibody therapies were viewed as one of the next frontiers in infectious disease treatment.

Origins of NeuTec Pharma

NeuTec Pharma was formed in 1997 in Manchester, England. The company specialized in genetically recombinant antibodies, which it branded as “grabs.” Unlike traditional pharmaceutical firms that relied heavily on chemical compound screening to discover antimicrobial agents, NeuTec pursued a biologically inspired approach.

Its strategy centered on studying patients who survived dangerous bacterial and fungal infections. By analyzing the antibodies naturally produced during recovery, NeuTec sought to identify particularly effective immune responses and recreate those antibodies in recombinant form for therapeutic use. This approach was positioned as potentially safer and more targeted than conventional antibiotics or antifungal agents.

The company’s research was heavily associated with the work of Professor John Burnie and collaborators at the University of Manchester. Manchester already possessed a strong biomedical research ecosystem, and NeuTec became part of a growing cluster of biotechnology innovation in Northern England during the late 1990s and early 2000s.

The company established itself at a time when antibiotic resistance was increasingly viewed as a looming global health crisis. Methicillin-resistant Staphylococcus aureus (MRSA), invasive candidiasis, and other opportunistic infections were causing significant concern among hospitals worldwide. NeuTec positioned itself as a company capable of changing how such infections could be treated.

The “Grab” Technology Concept

NeuTec’s central scientific innovation revolved around recombinant antibody fragments known internally as “grabs.” The company’s process differed from conventional pharmaceutical discovery methods in several important ways.

Traditional drug discovery often involves screening thousands or even millions of synthetic chemical compounds in hopes of identifying one with antimicrobial properties. NeuTec instead focused on naturally occurring immune responses. Scientists identified antibodies in recovered patients that appeared protective against dangerous infections. These antibodies were then cloned and engineered into recombinant therapeutic fragments.

NeuTec believed this strategy could offer several benefits:

• Greater specificity against pathogens
• Reduced toxicity compared to traditional antibiotics
• Lower likelihood of damaging healthy tissues
• Potential synergy with existing treatments
• Faster targeting of drug-resistant infections

The company also developed its proprietary FabTec© platform technology to streamline antibody discovery and development. FabTec combined patient antibody analysis, genetic sequencing, molecular biology, and custom bioinformatics software to rapidly identify therapeutic candidates.

At the time, this represented a highly modern biotechnology approach. Antibody therapies were already gaining traction in cancer treatment, but their use against fungal and bacterial infections remained relatively novel.

Manchester and the UK Biotechnology Environment

NeuTec Pharma emerged during an important period for British biotechnology. During the late 1990s and early 2000s, the United Kingdom experienced substantial growth in biotech startups and university-linked biomedical companies.

Manchester, in particular, was becoming increasingly recognized for biomedical research and pharmaceutical innovation. The city benefited from strong university research infrastructure, medical teaching hospitals, and government efforts to support life sciences commercialization.

NeuTec’s presence in Manchester helped position the city as part of the UK’s emerging biotechnology corridor outside of London and Cambridge. The company’s scientific ambitions, international clinical trials, and eventual acquisition by Novartis brought significant visibility to the regional biotech scene.

Mycograb®: NeuTec’s Most Famous Product

NeuTec’s most prominent investigational therapy was Mycograb®, a recombinant human antibody fragment targeting fungal heat shock protein 90 (hsp90).

The drug was developed primarily for invasive candidiasis, a serious systemic fungal infection frequently seen in:

• Cancer patients
• Bone marrow transplant recipients
• Premature infants
• Intensive care patients
• Individuals with compromised immune systems
• Patients undergoing dialysis

Invasive candidiasis carried high mortality rates, particularly among vulnerable hospitalized patients. Existing treatments such as amphotericin B were effective but often highly toxic, particularly to the kidneys and liver.

NeuTec promoted Mycograb® as a potentially safer and more effective adjunctive therapy. Laboratory studies suggested the therapy worked synergistically with amphotericin B, improving fungal clearance while potentially reducing mortality.

One of the most significant moments in NeuTec’s history came in 2004 when the company announced positive results from a multinational double-blind placebo-controlled clinical trial involving 139 patients across Europe and the United States.

The reported results attracted considerable industry attention:

• 84% overall response rate in the Mycograb® group
• 48% response rate in the control group
• Faster fungal clearance
• Reduced candida-related mortality

These findings positioned Mycograb® as one of the most closely watched antifungal drug candidates of its era.

NeuTec also explored Mycograb® for additional indications, including:

• Invasive aspergillosis
• Cryptococcal meningitis in AIDS patients
• Breast cancer

The cancer research angle stemmed from the importance of hsp90 proteins in tumor cell survival. Researchers believed Mycograb® might interfere with cancer growth pathways while avoiding some of the toxicities associated with chemical hsp90 inhibitors.

Aurograb® and the MRSA Crisis

NeuTec’s second major product candidate was Aurograb®, designed to target Staphylococcus aureus infections, including MRSA.

During the early 2000s, MRSA had become a major public health issue. Hospitals across Europe, North America, and Asia were reporting increasing rates of antibiotic-resistant staph infections. Media coverage frequently referred to “superbugs,” and healthcare systems faced mounting concerns over infections resistant to conventional antibiotics.

Aurograb® was developed to work synergistically with vancomycin, then considered one of the last-resort treatments for MRSA infections. NeuTec claimed the therapy demonstrated activity not only against MRSA but also against strains showing reduced sensitivity to vancomycin.

Clinical trials for Aurograb® expanded across multiple European countries. The company completed Phase II studies and later advanced into a large Phase III trial involving 35 centers across six countries.

At the time, the possibility of an antibody-enhanced therapy against MRSA generated substantial optimism among infectious disease researchers and investors alike.

Orphan Drug Status and Regulatory Progress

NeuTec achieved several important regulatory milestones that helped elevate its profile internationally.

Mycograb® received Orphan Drug Status from both:

• The U.S. Food and Drug Administration
• The European Medicines Agency

Orphan Drug designation is granted to therapies targeting rare but serious conditions. The status can provide regulatory incentives, market exclusivity benefits, and financial advantages for developers.

NeuTec also submitted Investigational New Drug applications and pursued market authorization filings in Europe. These regulatory achievements reinforced the perception that the company had genuine commercial potential rather than being merely an experimental research venture.

Intellectual Property and Scientific Output

NeuTec invested heavily in intellectual property protection. The company reportedly filed 18 patent families and secured more than 70 patents worldwide related to its antibody technologies and therapeutic targets.

The company’s scientific leadership also published extensively in peer-reviewed journals covering:

• Fungal heat shock proteins
• Recombinant antibodies
• Antifungal therapy
• Antibody engineering
• MRSA treatment strategies

These publications helped establish NeuTec’s scientific credibility within the infectious disease and biotechnology communities.

Researchers associated with the company contributed to journals such as:

• FEMS Immunology & Medical Microbiology
• Vaccine
• Expert Opinion on Biological Therapy
• Antimicrobial Agents and Chemotherapy

This scientific output played an important role in attracting investor interest and industry attention.

Acquisition by Novartis

In July 2006, Novartis acquired NeuTec Pharma in a deal reportedly valued at approximately $569 million.

The acquisition was viewed as a major validation of NeuTec’s scientific platform and clinical pipeline. At the time, Novartis was aggressively expanding its biotechnology capabilities and infectious disease portfolio.

Industry analysts viewed the purchase as strategically important because it gave Novartis access to:

• Novel antibody-based anti-infective technologies
• Late-stage clinical candidates
• Intellectual property related to recombinant antibody fragments
• Expertise in antifungal and antibacterial biologics

The deal generated considerable media coverage in pharmaceutical and financial circles. It also underscored growing industry recognition that antimicrobial resistance represented a major future market opportunity.

For Manchester and the broader UK biotech ecosystem, the acquisition served as evidence that British biotechnology firms could attract major international pharmaceutical investment.

Decline of the Product Pipeline

Despite the optimism surrounding the acquisition, NeuTec’s product pipeline eventually encountered serious difficulties.

In 2008, Novartis discontinued development of Aurograb®. Analysts began questioning whether the acquisition price had been justified.

Then in 2010, Novartis abandoned development of Mycograb® as well. Reports suggested concerns involving efficacy, manufacturing complexities, and broader commercial viability contributed to the decision.

The discontinuation of both leading products transformed NeuTec into a cautionary example of the enormous risks involved in pharmaceutical research and development.

Even promising clinical data does not guarantee eventual approval or commercial success. Biotechnology companies frequently face challenges involving:

• Manufacturing scalability
• Regulatory hurdles
• Safety concerns
• Statistical interpretation of clinical trials
• Commercial competitiveness
• Cost-benefit calculations by larger pharmaceutical firms

NeuTec’s rise and fall illustrated how volatile the biotechnology sector can be, even for companies backed by major scientific research and multinational pharmaceutical investment.

NeuTecPharma.com as a Historical Archive

After the company disappeared, the original NeuTecPharma.com domain eventually expired. Much of the information about NeuTec vanished from the public web.

The later restoration effort aimed to preserve archived portions of the original site using material recovered from web archives and cached historical sources. This preservation initiative reflects a broader movement to save historically significant early internet content before it disappears permanently.

Many biotechnology startups from the early web era left behind little digital trace after acquisitions, mergers, or closures. Archived corporate websites therefore provide valuable historical insight into:

• Early biotech marketing strategies
• Scientific communication practices
• Investor messaging
• Pharmaceutical industry optimism during the genomics boom
• Evolution of antibody therapies

For historians of biotechnology and digital preservation advocates, NeuTecPharma.com represents an example of how corporate internet history can otherwise vanish entirely.

The Broader Context of Antibody Therapies

Although NeuTec’s own products ultimately failed to reach long-term commercial success, many of the company’s underlying scientific concepts later became increasingly mainstream.

Antibody therapies are now widely used across medicine for:

• Cancer immunotherapy
• Autoimmune diseases
• Infectious disease treatment
• Inflammatory disorders
• Rare genetic conditions

The biotechnology industry has increasingly embraced biologics and targeted therapies over purely chemical drug discovery models.

In some ways, NeuTec can be viewed as part of an early generation of companies attempting to apply antibody engineering to infectious disease treatment before the field fully matured.

Its work anticipated broader trends in:

• Precision medicine
• Immunotherapy
• Biologic pharmaceuticals
• Personalized medicine
• Targeted antimicrobial approaches

Scientific and Cultural Significance

NeuTec Pharma occupies an interesting niche in biotechnology history. While it never became a lasting commercial success, the company contributed to important conversations about:

• Antimicrobial resistance
• Hospital-acquired infections
• Recombinant antibody therapeutics
• Biopharmaceutical innovation
• The economics of drug development

The company also reflected the enormous optimism surrounding biotechnology during the late 1990s and early 2000s. Investors, scientists, and pharmaceutical companies increasingly believed advanced biologics would revolutionize medicine.

Although NeuTec ultimately disappeared into pharmaceutical history, its ambitious scientific vision captured many of the hopes and anxieties of that period.

Its story also demonstrates how biotechnology innovation often proceeds through cycles of experimentation, failure, adaptation, and eventual broader industry evolution.

Media Coverage and Industry Attention

At its peak, NeuTec attracted attention from:

• Pharmaceutical industry analysts
• Biotechnology investors
• Medical journals
• Healthcare publications
• Financial press
• Infectious disease researchers

Coverage often emphasized:

• The growing MRSA crisis
• Hospital fungal infections
• Drug-resistant pathogens
• Novel biologic therapies
• The commercial promise of antibody drugs

The Novartis acquisition particularly elevated the company’s visibility internationally.

Even after the discontinuation of Mycograb® and Aurograb®, NeuTec continued to be referenced in discussions about biotech acquisition risks and pharmaceutical R&D uncertainty.

Lessons from the NeuTec Story

NeuTec Pharma’s trajectory offers several important lessons about the biotechnology industry.

First, promising science does not always translate into approved therapies. Drug development remains extraordinarily difficult, expensive, and unpredictable.

Second, the company demonstrated the growing importance of biologics and recombinant antibody technologies, trends that have since become central to modern pharmaceutical development.

Third, the story illustrates how regional biotech ecosystems like Manchester’s can produce globally significant innovation.

Finally, the preservation of NeuTecPharma.com highlights the importance of digital archiving. Many influential early biotech companies no longer exist online, making preserved websites valuable historical resources.

~~~

NeuTecPharma.com is far more than a forgotten pharmaceutical domain. It represents the preserved digital footprint of a biotechnology company that once stood at the forefront of antibody-based infectious disease therapy.

Founded in Manchester in 1997, NeuTec Pharma Ltd pursued ambitious goals involving recombinant antibodies designed to combat fungal infections and antibiotic-resistant bacteria. Its products Mycograb® and Aurograb® generated international attention, advanced into major clinical trials, and eventually attracted acquisition by Novartis in a deal worth hundreds of millions of dollars.

Although the products ultimately failed to achieve lasting commercial success, NeuTec’s research reflected broader scientific trends that later transformed the pharmaceutical industry. The company’s work anticipated the rise of biologics, targeted therapies, and immune-based treatment strategies that now dominate many areas of modern medicine.

Today, the restored NeuTecPharma.com serves as a historical archive preserving a fascinating chapter in biotechnology history — one that captures both the promise and the uncertainty of pharmaceutical innovation during the early twenty-first century.

NeuTecPharma.com